Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Liabilities and Shareholders Equity (2019 - 2025)

Pulmonx (LUNG) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $138.3 million as the latest value for Q3 2025.

  • Quarterly Liabilities and Shareholders Equity fell 17.4% to $138.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $451.9 million through Sep 2025, down 33.78% year-over-year, with the annual reading at $162.8 million for FY2024, 8.4% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $138.3 million at Pulmonx, down from $150.7 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $255.3 million in Q1 2021, with the low at $138.3 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $188.7 million, with a median of $181.4 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity fell 17.65% in 2022, then decreased 8.21% in 2023.
  • Over 5 years, Liabilities and Shareholders Equity stood at $235.2 million in 2021, then fell by 17.65% to $193.7 million in 2022, then fell by 8.21% to $177.8 million in 2023, then decreased by 8.4% to $162.8 million in 2024, then decreased by 15.09% to $138.3 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $138.3 million, $150.7 million, and $162.8 million for Q3 2025, Q1 2025, and Q4 2024 respectively.